| scholarly article | Q13442814 |
| P50 | author | David Eidelberg | Q5233311 |
| P2093 | author name string | Kathleen L Poston | |
| P2860 | cites work | Behind the scenes of functional brain imaging: a historical and physiological perspective | Q28260353 |
| Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases | Q29614910 | ||
| Transplantation of embryonic dopamine neurons for severe Parkinson's disease | Q29617304 | ||
| Assessment of the progression of Parkinson's disease: a metabolic network approach | Q31130371 | ||
| The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service | Q33183516 | ||
| Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies | Q33393896 | ||
| Metabolic brain networks in neurodegenerative disorders: a functional imaging approach | Q33504970 | ||
| Abnormal regional brain function in Parkinson's disease: truth or fiction? | Q34160477 | ||
| Changes in motor subtype and risk for incident dementia in Parkinson's disease | Q34517430 | ||
| Levodopa and the progression of Parkinson's disease | Q34553278 | ||
| Circuits and circuit disorders of the basal ganglia | Q34599488 | ||
| Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial | Q34640765 | ||
| Thalamic metabolism and symptom onset in preclinical Huntington's disease | Q34692568 | ||
| Clinical outcomes of progressive supranuclear palsy and multiple system atrophy | Q34767058 | ||
| Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease | Q34770504 | ||
| Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease | Q35679727 | ||
| Changes in network activity with the progression of Parkinson's disease | Q35679748 | ||
| Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease | Q35679817 | ||
| Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. | Q35683286 | ||
| Metabolic brain networks associated with cognitive function in Parkinson's disease | Q35684482 | ||
| Network modulation in the treatment of Parkinson's disease | Q35694166 | ||
| Cognitive dysfunction and dementia in Parkinson's disease | Q35916460 | ||
| Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease | Q36288717 | ||
| Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease | Q36739358 | ||
| Gene transfer therapy for neurodegenerative disorders | Q36773753 | ||
| Deep brain stimulation for the treatment of atypical parkinsonism | Q36894736 | ||
| Network biomarkers for the diagnosis and treatment of movement disorders | Q37327010 | ||
| The metabolic anatomy of tremor in Parkinson's disease | Q39444846 | ||
| Metabolic correlates of pallidal neuronal activity in Parkinson's disease | Q39453972 | ||
| Neuronal activity of the human subthalamic nucleus in the parkinsonian and nonparkinsonian state. | Q42440222 | ||
| Imaging essential tremor | Q43076413 | ||
| Metabolic correlates of levodopa response in Parkinson's disease | Q43820136 | ||
| Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET. | Q43999153 | ||
| Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. | Q44428226 | ||
| The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years | Q44801054 | ||
| The association of incident dementia with mortality in PD. | Q44953420 | ||
| Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years | Q45155172 | ||
| Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations | Q45302799 | ||
| Voxel based comparison of glucose metabolism in the differential diagnosis of the multiple system atrophy using statistical parametric mapping | Q46520473 | ||
| FDG PET in the differential diagnosis of parkinsonian disorders | Q46546312 | ||
| Comparison of cerebral glucose metabolism between multiple system atrophy Parkinsonian type and Parkinson's disease | Q46547561 | ||
| Metabolic correlates of subthalamic nucleus activity in Parkinson's disease | Q46653986 | ||
| Abnormal metabolic networks in atypical parkinsonism | Q46815002 | ||
| Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease | Q48289094 | ||
| Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging | Q48354755 | ||
| Quantification of Parkinson's disease-related network expression with ECD SPECT. | Q48374366 | ||
| Differentiating between multiple system atrophy and Parkinson's disease by positron emission tomography with 18F-dopa and 18F-FDG. | Q48641864 | ||
| Progression of motor impairment and disability in Parkinson disease: a population-based study | Q48703656 | ||
| Prevalence of Parkinson's disease in the elderly: The Rotterdam Study | Q57782167 | ||
| The evolution of diagnosis in early Parkinson disease. Parkinson Study Group | Q64788289 | ||
| The metabolic topography of parkinsonism | Q72136177 | ||
| Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up | Q77627162 | ||
| P433 | issue | 1 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| Fluorodeoxyglucose Positron Emission Tomography | Q130273243 | ||
| P304 | page(s) | 55-64 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | PET clinics | Q26842869 |
| P1476 | title | FDG PET in the Evaluation of Parkinson's Disease | |
| P478 | volume | 5 |
| Q38093247 | Biomarkers for the diagnosis and management of Parkinson's disease |
| Q37693470 | Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. |
| Q57178030 | Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia |
| Q58612059 | Data-driven, voxel-based analysis of brain PET images: Application of PCA and LASSO methods to visualize and quantify patterns of neurodegeneration |
| Q34554452 | Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts |
| Q58572579 | Recent Advances in Biomarkers for Parkinson's Disease |
| Q92801358 | The Metabolic Activity of Caudate and Prefrontal Cortex Negatively Correlates with the Severity of Idiopathic Parkinson's Disease |
| Q30596699 | The history of cerebral PET scanning: from physiology to cutting-edge technology. |
| Q34096185 | The metabolic brain network in patients with Parkinson's disease based on (18)F-FDG PET imaging: evaluation of neuronal injury and regeneration. |
| Q50748881 | The utility of FDG-PET in the differential diagnosis of Parkinsonism. |
Search more.